Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma

被引:24
作者
Brinkman, M
Walter, J
Grein, S
Thies, MJW
Schulz, TW
Herrmann, M
Reiser, COA
Hess, J
机构
[1] Responsif GmbH, D-91056 Erlangen, Germany
[2] Univ Erlangen Nurnberg, Inst Clin Immunol & Rheumatol, Dept Med 3, D-91054 Erlangen, Germany
关键词
CD8 T cell response; pentamers; virus-like-particles; T cell epitope; melanoma therapy; TRP2 tumour antigen;
D O I
10.1007/s00262-004-0655-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Polyomavirus-like-particles (PLPs) are empty, non-replicative, non-infectious particles that represent a potent antigen-delivery system against malignant disease. Protective anti-tumour immunity can be induced under therapy conditions by subcutaneous (s.c.) treatment with particulate antigenic structures like chimerical polyomavirus-pentamers (PPs). These PPs displaying an immunodominant H-2K(b)-restricted ovalbumin (OVA)(257-264) epitope evoked nearly complete tumour remission in MO5 (B16-OVA) melanoma-bearing C57BL/6 mice by two s.c. applications in a weekly interval. The immunotherapeutic intervention started at day 4 after melanoma implant. Furthermore, 40% of melanoma-bearing mice vaccinated with heterologous PPs carrying a H-2K(b)-restricted cytotoxic T lymphocyte (CTL) epitope derived from of tyrosinase-related protein 2 (TRP2) survived similar treatment conditions. However, a late immunotherapeutic onset at day 10 post melanoma inoculation revealed no significant differences between the therapeutic values ( 40 - 60% survival) of VP1-OVA(252-270) and VP1-TRP2(180-192) PPs, respectively. These experiments underlined the capacity of PPs to break T cell tolerance against a differentially expressed self-antigen. As a correlate for preventive and therapeutic immunity against MO5 melanoma the number of OVA(257-264)- or TRP2(180-188)-specific CD8 T cells were significantly increased within the splenocyte population of treated mice as measured by H-2K(b)- OVA(257-264)-PE tetramer staining or appropriate ELISPOT assays, respectively. These results reveal that heterologous PLPs and even chimerical PPs represent highly efficient antigen carriers for inducing CTL responses underlining their potential as immunotherapeutics against cancer.
引用
收藏
页码:611 / 622
页数:12
相关论文
共 39 条
  • [31] Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma
    Shibagaki, N
    Udey, MC
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (04) : 850 - 860
  • [32] STUHLER G, 2002, T CELLS TUMOR IMMUNI
  • [33] Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: Comparison of prophylaxis and therapy
    van Elsas, A
    Sutmuller, RPM
    Hurwitz, AA
    Ziskin, J
    Villasenor, J
    Medema, JP
    Overwijk, W
    Restifo, NP
    Melief, CJM
    Offringa, R
    Allison, JP
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (04) : 481 - 489
  • [34] Induction of CD4+ T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells
    Wang, HY
    Fu, T
    Wang, G
    Zeng, G
    Perry-Lalley, DM
    Yang, JC
    Restifo, NP
    Hwu, P
    Wang, RF
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (11) : 1463 - 1470
  • [35] Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells
    Wang, RF
    Wang, HY
    [J]. NATURE BIOTECHNOLOGY, 2002, 20 (02) : 149 - 154
  • [36] Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
    Wang, RF
    Appella, E
    Kawakami, Y
    Kang, XQ
    Rosenberg, SA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (06) : 2207 - 2216
  • [37] Yamshchikov GV, 2001, INT J CANCER, V92, P703, DOI 10.1002/1097-0215(20010601)92:5<703::AID-IJC1250>3.3.CO
  • [38] 2-X
  • [39] Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity
    Zhou, YL
    Bosch, ML
    Salgaller, ML
    [J]. JOURNAL OF IMMUNOTHERAPY, 2002, 25 (04) : 289 - 303